Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India.
Neurofarba Department, Sezione di ScienzeFarmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Florence, Italy.
Arch Pharm (Weinheim). 2021 Jul;354(7):e2100028. doi: 10.1002/ardp.202100028. Epub 2021 Mar 24.
A novel series of imidazothiadiazole-linked benzenesulfonamide derivatives (5a-t) was synthesized and subjected for screening against the four physiologically and pharmacologically relevant human carbonic anhydrase (hCA) isoforms: hCA I, II, VA, and IX. The compounds selectively inhibited hCA I and II over hCA VA and IX. Furthermore, among the two cytosolic isoforms, hCA II was more effectively inhibited as compared with hCA I. The most active compounds were 5o with K = 0.246 µM and 5p with K = 0.376 µM against hCA II, whereas compound 5f showed good inhibition against both hCA I and II with K = 0.493 and 0.4 µM, respectively. This class of underexplored sulfonamides may be used to design isoform-selective CA inhibitors targeting enzymes of medicinal chemistry interest.
我们合成了一系列新型的咪唑并噻二唑连接的苯磺酰胺衍生物(5a-t),并对其进行了筛选,以检测其对四种生理和药理学相关的人碳酸酐酶(hCA)同工型的抑制作用:hCA I、II、VA 和 IX。这些化合物对 hCA I 和 II 具有选择性抑制作用,而对 hCA VA 和 IX 则没有抑制作用。此外,在两种胞质同工型中,hCA II 的抑制作用比 hCA I 更强。最具活性的化合物是 5o 和 5p,它们对 hCA II 的 K = 0.246 µM 和 K = 0.376 µM,而化合物 5f 对 hCA I 和 II 的抑制作用均较强,K 分别为 0.493 和 0.4 µM。这一类研究较少的磺酰胺类化合物可能被用于设计针对药物化学感兴趣的酶的同工型选择性 CA 抑制剂。